Tag: Pomalidomide

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Pomalidomide

Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

Added to Collection on: 2024-02-21 22:57:36

Tags for this article:

Orphan drugs
Multiple myeloma
Pomalidomide
Isatuximab
Selinexor
Daratumumab
Bortezomib
Carfilzomib
CASI Pharmaceuticals
AbbVie
Lenalidomide
Takeda Oncology

Click the tags to see associated articles and topics

View Article Details
FDA ODAC Committee Votes in Favor of Benefit-Risk Profile of Ide-Cel in Early R/R Myeloma

Added to Collection on: 2024-03-15 21:27:46

Tags for this article:

Orphan drugs
Multiple myeloma
Idecabtagene vicleucel
Carfilzomib
Elotuzumab
Daratumumab
Ixazomib
Lenalidomide
Pomalidomide
Proteasome inhibitor
Bortezomib
Cereblon E3 ligase modulator

Click the tags to see associated articles and topics

View Article Details
Ide-Cel Earns European Approval in Triple-Class Exposed Multiple Myeloma

Added to Collection on: 2024-03-21 21:01:54

Tags for this article:

Orphan drugs
Idecabtagene vicleucel
Bluebird bio
Multiple myeloma
Daratumumab
Proteasome inhibitor
Pomalidomide
Bristol-Myers Squibb

Click the tags to see associated articles and topics

View Article Details
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

Added to Collection on: 2024-06-21 22:47:30

Tags for this article:

Orphan drugs
Isatuximab
Multiple myeloma
Pomalidomide
Daratumumab
Lenalidomide
Dexamethasone
Bortezomib
Selinexor
Elotuzumab

Click the tags to see associated articles and topics

View Article Details
DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance

Added to Collection on: 2025-03-20 21:39:56

Tags for this article:

Orphan drugs
Daratumumab/hyaluronidase
Daratumumab
Isatuximab
Multiple myeloma
Carfilzomib
Lenalidomide
Elotuzumab
Pomalidomide
Proteasome inhibitor
Hyaluronidase
Bortezomib
Melphalan
Prednisone

Click the tags to see associated articles and topics

View Article Details
Elotuzumab Plus PVd May Be Effective in Relapsed, Refractory MM - Hematology Advisor

Added to Collection on: 2025-04-25 13:32:36

Tags for this article:

Orphan drugs
Elotuzumab
Multiple myeloma
SLAMF7
Bortezomib
Pomalidomide
Proteasome inhibitor
Carfilzomib
Filanesib

Click the tags to see associated articles and topics

View Article Details
Treatment Line Trends In The European Multiple Myeloma Therapeutics Market

Added to Collection on: 2025-05-13 10:37:09

Tags for this article:

Orphan drugs
Isatuximab
Multiple myeloma
Selinexor
Daratumumab
Carfilzomib
Lenalidomide
Elotuzumab
Pomalidomide
Proteasome inhibitor
Bortezomib
Dexamethasone

Click the tags to see associated articles and topics

View Article Details
Elotuzumab Plus PVd May Be Effective in Relapsed, Refractory MM

Added to Collection on: 2025-07-11 13:09:29

Tags for this article:

Orphan drugs
Elotuzumab
Multiple myeloma
SLAMF7
Bortezomib
Pomalidomide
Proteasome inhibitor
Carfilzomib
Filanesib

Click the tags to see associated articles and topics

View Article Details
Bristol touts its first pivotal celmod win | ApexOnco - Oncology Pipeline

Added to Collection on: 2025-09-24 19:52:28

Tags for this article:

Orphan drugs
Immunosuppressants
Aromatic amines
Phthalimides
Antineoplastic drugs
Lenalidomide
Dexamethasone
Daratumumab
Pomalidomide
Bortezomib
Carfilzomib
Multiple myeloma
Velcade
Bristol
Bristol-Myers Squibb
Revlimid

Click the tags to see associated articles and topics

View Article Details
High-Grade Glioma Pipeline 2025: Therapies Under - openPR.com

Added to Collection on: 2025-10-08 18:13:06

Tags for this article:

Brain tumor
Glioma
Glioblastoma
Pomalidomide
DNX-2401
GDC-0084
Regorafenib
Eflornithine
Lomustine
Berubicin
BMX-001
VAL-083

Click the tags to see associated articles and topics

View Article Details
Book a Demo